Introduction/Background Lymphedema is a chronic disorder with well-known impact on quality of life. Oncological treatments are the most frequent cause of lymphedema in developed countries.

Screening questionnaires are useful tools to detect patients at risk and prevent progression. Currently, there is no available Spanish questionnaire specifically designed to detect lower-limb lymphedema (LLL).

The aim of this study is to translate and develop a cross-cultural adaptation of the Self-Report Lower-Extremity Lymphedema Screening Questionnaire in Women (LELSQ) from the original English version to a Spanish version and validate it in women with gynecological cancer.

Methodology This is a prospective study that includes women from the Gynecological Oncologic Unit of the Hospital 12 de Octubre (Madrid, Spain) with gynecological tumors (ovarian, endometrial and cervical cancer) after undergoing surgical treatment including pelvic +/- paraaortic lymphadenectomy or pelvic sentinel lymph node.

After clinical assessment of the LLL, patients answer a first LELSQ translated version and then a second copy of the same questionnaire within 15 days.

A descriptive statistical analysis was made, using Cronbach’s alpha statistic to assess reliability and intraclass correlation coefficient (ICC) to determine consistency between observations (time lapse between the two questionnaires).

Results The first collected data (table 1) referred to 17 patients. 13 of them (76.5%) had endometrial cancer, 3 (17.6%) cervical cancer and 1 (5.9%) ovarian cancer.

The Cronbach’s alpha result was 0,915 and the ICC was 0,843, both showing good reliability and consistency of our test.

Conclusion

• The development of the Spanish version of the LELSQ may be helpful to detect LLL in clinical practice.

• Our pilot study shows that the Spanish version of the LELSQ has good reliability and consistency.

• Further analysis and patient inclusion should be done to complete the questionnaire validation.

Disclosures The authors of this abstract have no disclosures.